The Daily Toke

March 20, 2026

# THC & Politics: A Nation Divided on Regulation

Sweeping cannabis restrictions are taking effect across America this week, even as other states move toward legalization—a patchwork of policies that reveals the ongoing tension between voter-approved access and legislative crackdowns. Ohio's Senate Bill 56, which takes effect Friday, March 20, represents the most aggressive rollback yet of a voter-approved cannabis law. In 2023, 57% of Ohio voters approved recreational marijuana legalization. Now, less than three years later, lawmakers are capping THC potency in flower at 35% (down from unlimited), banning intoxicating hemp products entirely, eliminating legal protections for consumers, and criminalizing the possession of out-of-state cannabis. A referendum effort by Ohioans for Cannabis Choice to block the law failed to gather 250,000 signatures by Thursday's deadline, meaning the restrictions move forward despite significant opposition from cannabis retailers, breweries, and advocacy groups. 💰 MONEY MOVES The law threatens approximately 6,000 hemp and cannabis businesses that currently operate legally in Ohio, potentially displacing thousands of workers in a thriving legal market that voters explicitly approved.

Pennsylvania is walking a middle road. A state Senate committee, led by Republican Sen. Dan Laughlin, voted 10-1 to amend Senate Bill 49, adding provisions to ban most hemp-derived THC products—again, aligning with a federal policy change coming in November that would effectively eradicate the intoxicating hemp industry. Unlike Ohio's aggressive restrictions, Pennsylvania's approach focuses on creating a new Cannabis Control Board to oversee both medical marijuana and hemp, while also preparing infrastructure for eventual adult-use legalization. "Pennsylvania needs to make sure our laws remain consistent and enforceable," Laughlin said, framing the hemp ban as a closure of regulatory loopholes rather than a reversal of voter preference. The bill still allows for future adult-use marijuana legalization, keeping that door open while tightening control over the unregulated hemp market that exploded after the 2018 Farm Bill.

Meanwhile, Virginia and Connecticut are expanding access. Virginia lawmakers approved legislation last week establishing a regulated retail market for adult-use cannabis, finally creating the legal sales infrastructure that voters have waited for since 2021, when the state legalized possession of small amounts. Sales are expected to launch in 2027. Connecticut's legislature advanced House Bill 5350, which expands medical cannabis access to out-of-state patients, increases THC limits in infused beverages, streamlines business operations, and adds social equity protections. 🚀 THIS IS COOL Connecticut's bill also includes privacy protections preventing retailers from retaining customer age-verification data longer than 24 hours—a sensible privacy guardrail in an era of data collection concerns. New Hampshire, by contrast, let marijuana legalization and psilocybin therapy bills die without floor votes, killing chances for 2026 reform despite both proposals advancing in committee.

The national picture reflects a deeper political reality: federal hemp policy is driving state-level crackdowns, while legalization advocates lose momentum in hostile legislatures. 🤔 THINK ABOUT IT In 2023 and 2024, voter referendums passed in every state they appeared on—yet in legislatures controlled by cannabis opponents, those voter mandates are being systematically reversed or gutted through amendment. Ohio voters approved legalization. Pennsylvania voters haven't been asked. Virginia and Connecticut lawmakers are responding to constituent demand for legal markets. But in New Hampshire and Ohio, legislative majorities are defying or constraining what voters actually chose. As the federal government tightens hemp definitions in November, expect more states to follow Ohio and Pennsylvania's lead—banning intoxicating hemp products and creating tighter THC potency caps. The question facing cannabis advocates and legal businesses is whether voter-approved legalization can survive legislative backlash, or whether the window for legal cannabis in America closes before it ever really opened.

March 20, 2026

Ohio's strict new intoxicating hemp ban takes effect Friday, eliminating products that have flooded convenience stores and gas stations across the state—but not before a last-minute legal challenge and growing concerns from business owners about what exactly will be banned. A Franklin County judge denied an emergency request to halt the law late Wednesday, clearing the way for restrictions that cap THC at 0.4 milligrams per container and prohibit compounds like delta-8. The new rules, backed by Republican lawmakers and Gov. Mike DeWine, require all intoxicating hemp products to move exclusively into licensed dispensaries under the Ohio Division of Cannabis Control. But the timing and language of the ban has sparked real confusion: Adam Southward, co-owner of a CBD dispensary in Oregon, Ohio, said his store follows existing federal guidelines limiting THC to 0.3% by dry weight—yet the shift to a per-container measurement creates uncertainty about whether his compliant inventory will suddenly become illegal. "What kind of container are we talking about? A bag? A jar? It's just not very straightforward," he said. He worries the ambiguity could hurt customers relying on CBD for anxiety, pain relief, and neurological conditions—he cited one customer with Parkinson's disease who experienced better results from hemp products than hospital treatment.

💰 MONEY MOVES The Ohio restrictions arrive as other states race in opposite directions. South Carolina's Senate just passed legislation to regulate—not ban—hemp-derived THC gummies and drinks, racing against a May deadline when new federal restrictions take effect. Virginia faces a different crisis: more than 1,500 small businesses and independent farmers are urging Governor Abigail Spanberger to amend a cannabis bill that imposes a strict 2-milligram THC cap per package. The state's hemp industry, valued at roughly $562 million annually, could collapse under the new rules—which were added to the legislation in the final hours without public input or industry review. Neither law includes a transition period for existing businesses to sell through inventory or adapt operations, leaving retailers caught between federal deadlines and state shifts.

The chaos traces back to a spending bill President Trump signed last year that redefines hemp federally, capping total THC at 0.4 milligrams per container—a threshold industry advocates say will effectively eliminate the consumable cannabinoid market when it takes effect in November. 🚀 THIS IS COOL Yet the Centers for Medicare & Medicaid Services is preparing to launch a CBD coverage pilot program under Medicare that would allow up to 3 milligrams of total THC per serving—more than seven times the federal hemp limit. CMS Administrator Mehmet Oz previously said the CBD components could roll out as early as April. A CMS spokesperson told Cannabis Wire the agency "will adjust its definition in accordance with the law," but the apparent conflict raises questions about how federal policy will coherently apply across insurance, state regulations, and retail markets when the November deadline arrives.

🤔 THINK ABOUT IT The legislative chaos reveals something worth considering: states are simultaneously trying to restrict hemp products while federal health agencies prepare to cover them for medical patients. Some jurisdictions ban delta-8 outright; others are negotiating how to keep it legal; Medicare is about to cover CBD products that contain more THC than federal hemp law technically allows. The underlying tension isn't really about the plant—it's about how to regulate a product that exists in a legal gray zone created by the 2018 farm bill. Ohio chose prohibition. South Carolina chose regulation. Virginia faces potential business extinction. And the federal government is preparing a healthcare program that contradicts its own hemp restrictions. These aren't abstract policy debates—they're happening in real time, affecting thousands of small businesses, farmers, and customers who depend on these products for legitimate wellness and medical reasons.

The Ohio law is scheduled to take effect unless the Ohio Supreme Court intervenes. The court is currently reviewing whether DeWine exceeded his authority when he removed a provision that would have allowed breweries and restaurants to continue selling THC-infused beverages through year-end. Meanwhile, a new lawsuit filed just before the midnight deadline seeks to block the entire restriction. Businesses, patients, and policymakers across multiple states are watching to see whether bans or regulation become the model going forward—and whether the federal government's contradictory hemp policy will eventually force national clarity or leave states operating in permanent legal limbo.

March 20, 2026

Largest cannabis mental health study in 45 years finds no evidence the drug treats anxiety, depression, or PTSD—despite roughly half of the 27 percent of North Americans using medical cannabis saying they take it specifically for those conditions. The landmark review, published in The Lancet Psychiatry and led by Dr. Jack Wilson at the University of Sydney's Matilda Centre, analyzed 54 randomized controlled trials between 1980 and 2025, making it the most comprehensive examination of cannabinoids' psychiatric safety and effectiveness to date. 🚀 THIS IS COOL The researchers did identify some promising areas: medicinal cannabis may help reduce cannabis use disorder itself (similar to how methadone treats opioid addiction), and showed low-quality evidence for benefits in autism, insomnia, and Tourette's syndrome. But the evidence for the three most common reasons people are prescribed cannabis—anxiety, depression, and PTSD—simply doesn't exist, and Dr. Wilson warned that routine use could actually worsen mental health outcomes, increasing psychosis risk and cannabis use disorder while delaying access to proven treatments.

The findings arrive amid a massive expansion in cannabis prescriptions. Australia alone has recorded over one million prescription approvals in recent years, with medicinal cannabis sales tripling over the past four years. More than 700,000 Australians reported using the drug for mental health and substance use conditions, yet the majority of products prescribed—particularly in Australia—aren't registered with the Therapeutic Goods Administration, meaning they've never undergone rigorous testing. The research gap is particularly stark: for some conditions like depression, researchers found not a single high-quality trial available for analysis. 🤔 THINK ABOUT IT Millions are self-medicating with a substance that lacks scientific support for its most popular uses, while cannabis remains Schedule I federally in the United States—a classification originally recommended *against* by Nixon's own Shafer Commission in 1970.

Meanwhile, the federal government is quietly moving forward with cannabis access through a different door. The Centers for Medicare and Medicaid Services announced a pilot program that will allow CBD products containing up to 3 milligrams of THC per serving to be provided to Medicare beneficiaries at no cost if recommended by a doctor. 💰 MONEY MOVES The program, announced in December by Mehmet Oz alongside President Trump, could extend coverage to millions of seniors, though critical details remain unclear—including how CMS determined the 3-milligram threshold, what quality-control standards will apply, and how the program might conflict with a new federal hemp definition scheduled for November that bans products with more than 0.4 milligrams of THC per container. The FDA has signaled it needs a new regulatory pathway for CBD oversight, but Congress hasn't created one yet, leaving the pilot operating in a regulatory gray zone where state and local laws vary dramatically.

The contrast between what people believe cannabis does and what science shows it actually does highlights a fundamental research failure. Cannabis has been restricted as Schedule I for over 50 years, which severely limited the ability of scientists to conduct the large, well-funded clinical trials that establish medical safety and efficacy—the gold standard that medicine relies on for every other treatment. The result: public embrace of cannabis for mental health has wildly outpaced the evidence. Dr. Wilson emphasized that without robust medical and counseling support, routine use of medicinal cannabis for conditions like autism and insomnia "are rarely justified," and that in the absence of evidence, cannabis shouldn't be approved for anxiety, depression, and PTSD at all. The disconnect reveals something deeper: cannabis legalization and medical expansion happened through political and market forces, not through the methodical clinical evidence-building that typically precedes drug approvals. Now researchers are scrambling to answer questions the public thought were already settled.

March 20, 2026

Texas hemp businesses are bracing for a seismic market disruption set to hit March 31, when the Texas Department of State Health Services' newly finalized regulations take effect, fundamentally reshaping how the state measures THC content and effectively banning smokable cannabis products that have fueled a $10–12 billion annual industry. The new rules count THCA—tetrahydrocannabinolic acid, a non-psychoactive compound that converts to THC when heated—as part of "total THC" for regulatory purposes, a testing standard shift that will eliminate virtually all smokable hemp flower and extracts from legal retail shelves while leaving edibles and infused drinks largely untouched. 💰 MONEY MOVES Mark Bordas, executive director of the Texas Hemp Business Council, laid out the stakes plainly: "You're talking about shuttering stores—if these stay in place—that employ over 50,000 Texans. You're talking about major market disruption to an industry that generates over $10–12 billion a year." Store operators report that smokable products represent 60–70% of their sales, with THCA products alone accounting for 35–50% of revenue at many locations, meaning compliance with the new rules could force closures before April arrives.

Governor Greg Abbott's September 2025 executive order directing these stricter regulations came after he vetoed Senate Bill 3, which would have banned hemp-derived THC products outright during the 2025 legislative session.

Veterans and customers relying on faster-acting smokable products face genuine health consequences from this approach. Allen Kirk, managing partner at Full Spectrum hemp retail in San Angelo, noted that "a smokeable item can provide instant relief, whereas gummies or oils take 45 minutes to an hour and a half to work," a medically relevant distinction for veterans managing PTSD and chronic pain using legal THC products. 🤔 THINK ABOUT IT When regulators effectively ban a zero-overdose product while alcohol kills roughly 95,000 Americans annually and prescription opioids kill over 16,000 per year, does "consumer protection" mean what the marketing suggests? Kirk and other operators also flagged a practical risk: removing legal smokable products doesn't eliminate demand—it redirects it toward unregulated street alternatives where products go untested and consumers lose the safety protections they currently enjoy in the legal market.

The timing compounds the disruption. Retailers have roughly two weeks to clear smokable inventory, reprogram their business models, and absorb licensing fee increases that dwarf previous costs: retail fees jump from $155 to $5,000 annually, while manufacturer fees climb to $10,000 per facility. One anonymous hemp shop owner told reporters the new rules "will effectively shut down our businesses overnight." Texas has roughly 8,000 registered hemp retailers, and while attorney Andrea Steel reported that law enforcement raids have affected "a small fraction" of them since August 2024, those raids have intensified as the regulatory pressure mounted—a pattern that industry advocates believe signals enforcement coordination with the new rules taking effect.

The Texas situation reflects a broader national pattern of state-level hemp policy tightening even as federal rescheduling remains stalled. Congressional researchers released an updated analysis noting that marijuana rescheduling from Schedule I to Schedule III—which the Biden administration recommended and which Trump's executive order directed be expedited—would not automatically bring state-legal cannabis industries into federal compliance without additional legislative action. South Carolina lawmakers just passed a bill regulating THC drinks and gummies to prevent a May federal deadline that would wipe out most of the state's hemp industry, while Ohio failed to block new hemp restrictions that took effect March 20. Connecticut's legislature, meanwhile, advanced a bill to expand out-of-state medical access and revise hemp testing standards—a divergent approach showing that states are choosing fundamentally different regulatory paths even as federal policy remains in limbo. The hemp market, currently operating in a legal gray zone between state legalization and federal Schedule I classification, faces accelerating instability as states impose conflicting rules and the federal government delays definitive action on rescheduling.